BioPlus leader offers information, commentary via Dr. Vogt’s BioBlog
ALTAMONTE SPRINGS, Fla. — As a relatively new facet of the pharmacy profession, specialty pharmacy is constantly developing, prompting the leader of one provider to go online to keep patients and physicians up to date.
BioPlus Specialty Pharmacy president and CEO Stephen Vogt has launched Dr. Vogt’s BioBlog, providing commentary and information to patients and physicians about developments in specialty pharmacy. Vogt will post weekly updates with his perspective and experience about current advancements and events in specialty pharmacy related to such chronic illnesses as hepatitis, cancer, rheumatoid arthritis and others.
“Dr. Vogt’s experience, knowledge and skill in this area give him a unique perspective on new developments in our field,” BioPlus director of pharmacy services Nick Maroulis said. “For example, instead of just hearing about a new drug being released, readers of Dr. Vogt’s BioBlog will get an understanding of what the new drug will mean to their lives and disease treatment.”
The blog can be accessed at BioPlusSP.com.
Takeda resubmits new drug applications for Type 2 diabetes treatments
OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.
Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.
The FDA will review the applications over the next six months, the drug maker said.
Impax enrolls patients into late-stage trial for Parkinson’s treatment
HAYWARD, Calif. — The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.
Impax Pharmaceuticals said Tuesday that it had enrolled patients in ASCEND-PD, a phase-3 trial of IPX066 that will compare the drug with carbidopa-levodopa and entacapone in patients with advanced Parkinson’s. IPX066 is an extended-release formulation of carbidopa-levodopa in capsule form.
“We are extremely pleased to have completed enrollment in ASCEND-PD, which is the third phase-3 trial of IPX066 in [Parkinson’s disease] subjects,” Impax Pharmaceuticals chief scientific officer Suneel Gupta said. “The study compares IPX066 to another commonly used medication in advanced PD and is intended to provide further safety and efficacy data on IPX066.”